Current Status of Angiogenic Cell Therapy and Related Strategies Applied in Critical Limb Ischemia |
| |
Authors: | Lucía Beltrn-Camacho Marta Rojas-Torres M
Carmen Durn-Ruiz |
| |
Affiliation: | 1.Biomedicine, Biotechnology and Public Health Department, Cádiz University, 11519 Cadiz, Spain; (L.B.-C.); (M.R.-T.);2.Institute of Research and Innovation in Biomedical Sciences of Cadiz (INIBICA), 11009 Cádiz, Spain |
| |
Abstract: | Critical limb ischemia (CLI) constitutes the most severe form of peripheral arterial disease (PAD), it is characterized by progressive blockade of arterial vessels, commonly correlated to atherosclerosis. Currently, revascularization strategies (bypass grafting, angioplasty) remain the first option for CLI patients, although less than 45% of them are eligible for surgical intervention mainly due to associated comorbidities. Moreover, patients usually require amputation in the short-term. Angiogenic cell therapy has arisen as a promising alternative for these “no-option” patients, with many studies demonstrating the potential of stem cells to enhance revascularization by promoting vessel formation and blood flow recovery in ischemic tissues. Herein, we provide an overview of studies focused on the use of angiogenic cell therapies in CLI in the last years, from approaches testing different cell types in animal/pre-clinical models of CLI, to the clinical trials currently under evaluation. Furthermore, recent alternatives related to stem cell therapies such as the use of secretomes, exosomes, or even microRNA, will be also described. |
| |
Keywords: | critical limb ischemia neovascularization angiogenesis arteriogenesis cell therapy secretomes |
|
|